Trial Profile
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Binge-eating disorder; Obesity
- Focus Therapeutic Use
- 14 Apr 2023 Status changed from active, no longer recruiting to completed.
- 27 Jul 2022 Planned End Date changed from 1 Oct 2023 to 1 Dec 2022.
- 18 Feb 2022 Status changed from recruiting to active, no longer recruiting.